[1] Kim PS, Hafner R. Viewpoint:Challenges and opportunities in tuberculosis research[J]. Journal of Infectious Disease, 2012, 205(suppl. 2):347-352. [2] Amaral L, Molnar J. Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine[J]. In Vivo, 2012, 26(2):231-236. [3] Villemagne B, Crauste C, Flipo M, et al. Tuberculosis:the drug development pipeline at a glance[J]. European Journal of Medicinal Chemistry, 2012, 51(5):1-16. [4] Fenical W, Jensen PR. Developing a new resource for drug discovery:marine actinomycete bacteria[J]. Nature Chemical Biology, 2006, 2(12):666-673. [5] 焦炳华, 穆军, 许强芝, 等. 海洋微生物来源新抗生素的研究[J]. 抗感染药学, 2004, 1(1):1-9. [6] Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A:a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora[J]. Angewandte Chemie International Edition, 2003, 42(3):355-357. [7] Bister B, Bischoff D, et al. Abyssomicin C-A polycyclic antibiotic from a marine Verrucosispora strain as an inhibitor of the p-aminob-enzoic acid/tetrahydrofolate biosynthesis pathway[J]. Angewandte Chemie International Edition, 2004, 43(19):2574-2576. [8] Kwonhc HC, Kauffman CA, Jensen PR, et al. Fenical W. Marinomycins A-D antitumour antibiotics of a new structure class from a marine actinomycete of the recently discovered genus “Marinispora”[J]. Journal of the American Chemical Society, 2006, 128(5):1622-1632. [9] Olano C, Mendez C, Salas JA, et al. Antitumor compounds from marine actinomycetes[J]. Marine Drugs, 2009, 7(2):210-248. [10] Rahman H, Austin B, Mitchell WJ, et al. Novel anti-infective compounds from marine bacteria[J]. Marine Drugs, 2010, 8(3):498-518. [11] Fattorusso E, Taglialatela SO. Marine antimalarials[J]. Marine Drugs, 2009, 7(2):130-152. [12] Stanley SA, et al. Identification of novel inhibitors of M. tuberculo-sis growth using whole cell based high-throughput screening[J]. ACS Chemical Biology, 2012, 7(8):1377-1384. [13] 李仲兴. 耻垢分枝杆菌群感染及其菌种鉴定[J]. 中华检验医学杂志, 2006, 29(5):475-477. [14] 关艳, 杨延辉, 等. 以耻垢分枝杆菌为模式菌快速筛选新型抗结核药物[J]. 中国新药杂志, 2014, 23(10):1175-1187. [15] 东秀珠, 蔡妙英. 常见细菌系统鉴定手册[M]. 北京:科学出版社, 2001:162-364. [16] 萨姆布鲁克, 拉塞尔著;黄培堂, 等译. 分子克隆实验指南[M]. 第3版, 北京:科学出版社, 2008. [17] Tamura K, Dulley J, Nei M, et al. MEGA4:molecular evolutionary genetics analysis(MEGA)software verison 4. 0[J]. Molecular Biology Evolution, 2007, 24(8):1596-1599. [18] 鄂征. 组织培养与分子细胞学技术[M]. 北京:北京出版社, 1995. [19] 刘全永, 胡江春, 薜德林, 等. 海洋微生物生物活性物质研究[J]. 应用生态学报, 2002, 13(7):901-905. [20] Goodfellow M, Fiedler HP. A guide to successful bioprospecting:informed by actinobacterial systematics[J]. Antonie Van Leeuwenhoek, 2010, 98(2):119-142. [21] 王宏梅, 赵心清. 可培养海洋放线菌生物多样性研究进展[J]. 微生物学通报, 2007, 34(5):996-1000. [22] Ergan B, Coplu L, Alp A, et al. Mycobacterium smegmatis pneumonia[J]. Respirology, 2004, 9(2):283-295. [23] Lechevalier HA, Lechevalier MP, Gerber NN, et al. The actinomycetes[M]Jena:Gustav-Fische, 1970. [24] Stackebrandt E, Woese CR. Towards a phylogeny of the actinomycetes and related organisms[J]. Current Microbiology, 1981, 5(4):197-202. [25] Panchanathan M, Kyong-Hwa K, Kannan S, et al. Marine actinobacteria:An important source of bioactive natural products[J]. Environmental Toxicology and Pharmacology, 2014, 38(1):172-188. [26] Lahouuma A, Aouichea N, Bourasab C, et al. Antifungal activity of a Saharan strain of Actinomadura sp. ACD1 against toxigenic fungi and other pathogenic microorganisms[J]. Journal of Medical Mycology, 2016, 26(3):193-200. [27] Mazzei E, Iorio M, Maffioli, et al. Characterization of madurastatin C1, a novel siderophore from Actinomadura sp.[J]. The Journal of Antibiotics, 2012, 65(5):267-269. [28] Motoki T, Keiichiro M, Shams T, et al. JBIR-65, a new diterpene, isolated from a sponge-derived Actinomadura sp. SpB081030SC-15[J]. Cheminform, 2010, 41(49):401. [29] Han XX, Cui CB, Gu QQ, et al. ZHD-0501, a novel naturally occurring staurosporine analog from Actinomadum sp.[J]. Tetrahedron Letters, 2015, 46(36):6137-6140. [30] Harada K, Tomita K, Fujii K, et al. Isolation and structural characterization of siderophores, madurastatins, produced by a pathogenic Actinomadura madurae[J]. Journal of Antibiotics, 2004, 57(2):125-135. [31] Dirlam JP, Belton AM, Bordner J, et al. CP-82, 996, a novel diglycoside polyether antibiotic related to monensin and produced by Actinomadura sp.[J]. Journal of Industrial Microbiology, 1990, 6(2):135-177. [32] Badji B, Zitouni A, Mathieu F, et al. Antimicrobial compounds produced by Actinomadura sp. AC104 isolated from an Algerian Saharan soil[J]. Canadian Journal of Microbiology, 2006, 52(4):373-382. 33] Maskey RP, Li FC, Qin S, Fiebig HH, Laatsch H. Chandrananimy-cins A ~ C:Production of novel anti-cancer antibiotics from a marine Actinomadura sp. isolate M048 by variation of medium composition and growth conditions[J]. Journal of Antibiotics, 2003, 56(7):373-382. [34] Chakapong I, Aibrohim D, Sumalee S, et al. 3-Oxyanthranilic acid derivatives from Actinomadura sp. BCC27169[J]. Cheminform, 2014, 45(36):102. |